The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.00
Bid: 42.50
Ask: 43.50
Change: 0.10 (0.23%)
Spread: 1.00 (2.353%)
Open: 43.00
High: 44.10
Low: 42.50
Prev. Close: 44.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
29 Jul 2020 13:46

Avacta expands partnership with Daewoong to Covid-19 therapy

(Sharecast News) - Biotherapeutics and reagents developer Avacta Group announced an expansion of its collaboration and license agreement with Daewoong Pharmaceutical and AffyXell Therapeutics - the joint venture established in South Korea by the two companies - to develop stem cell treatments on Wednesday.

Read more
22 Jul 2020 17:57

UK TRADING UPDATE SUMMARY: Virus Hits Mears But Tristel Gets Boost

UK TRADING UPDATE SUMMARY: Virus Hits Mears But Tristel Gets Boost

Read more
22 Jul 2020 16:13

Avacta's Covid test collaboration with Adeptrix accepted into CONDOR

(Sharecast News) - Avacta Group has started work with the UK government's 'CONDOR' programme, it announced on Wednesday, to evaluate and clinically validate the high throughput Covid-19 bead-assisted mass spectrometry laboratory assay, developed with Adeptrix.

Read more
13 Jul 2020 11:23

Avacta Partners With Integumen To Detect Covid-19 In Waste Water

Avacta Partners With Integumen To Detect Covid-19 In Waste Water

Read more
13 Jul 2020 09:18

Avacta signs Covid sewage test deal with Integumen

(Sharecast News) - Biotherapeutics company Avacta Group has entered into a collaboration with its AIM peer Integumen, it announced on Monday, to evaluate recently-generated Affimer reagents that bind the SARS-CoV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert system to warn of localised Covid-19 outbreaks.

Read more
24 Jun 2020 13:55

IN BRIEF: Avacta Posts Positive Results For Covid-19 Detection Test

IN BRIEF: Avacta Posts Positive Results For Covid-19 Detection Test

Read more
24 Jun 2020 08:36

Avacta upbeat on evaluation of Covid-19 test strips

(Sharecast News) - Avacta Group announced on Wednesday that the first 'Affimer'-based rapid test strips to detect SARS-CoV-2 (Covid-19) spike protein had been developed and evaluated by its partners at Cytiva - formerly GE Healthcare Life Sciences - and reportedly showed positive initial performance data.

Read more
22 Jun 2020 08:52

'No-swab' saliva test for coronavirus piloted in Britain

LONDON, June 22 (Reuters) - A weekly coronavirus testing regime using a "no-swab" saliva test is being trialled in Southampton, southern England, and could result in a simpler and quicker way to detect outbreaks of the virus, the British governme...

Read more
18 Jun 2020 11:55

Avacta reports promising findings on potential Covid therapy

(Sharecast News) - Avacta Group announced on Thursday that collaborative work with the Centre for Virus Research at the University of Glasgow has shown that its 'Affimer' reagents, which bind to the SARS-COV-2 (Covid-19) virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus, and therefore provide a potential therapy for Covid-19 infection.

Read more
15 Jun 2020 15:52

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
9 Jun 2020 11:14

UK TRADING UPDATE SUMMARY: Omega Wins First Order For Antibody Test

UK TRADING UPDATE SUMMARY: Omega Wins First Order For Antibody Test

Read more
9 Jun 2020 09:30

Avacta's Covid-19 test reaches prototype stage

(Sharecast News) - Avacta said its Covid-19 antigen test had reached prototype stage and could detect the virus in model samples.

Read more
4 Jun 2020 14:31

Avacta To Raise GBP48 Million To Accelerate Development Of Therapies

Avacta To Raise GBP48 Million To Accelerate Development Of Therapies

Read more
4 Jun 2020 09:27

Avacta raising £45m to fund diagnostics and therapies pipeline

(Sharecast News) - Biotherapeutic and reagent developer Avacta Group announced its intention to raise up to £45m through a placing to institutional and other investors, a direct subscription with the company, and offers to retail and other investors via the PrimaryBid platform, it announced on Thursday.

Read more
20 May 2020 10:16

Avacta signs Covid-19 test distribution deal with Boohoo founders

(Sharecast News) - Avacta Group has entered into an exclusive distribution agreement with Medusa19 for direct-to-consumer sales of a saliva-based rapid test for the Covid-19 antigen, it announced on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.